Beyond Air price target lowered to $2 from $6 at JonesResearch

JonesResearch lowered the firm’s price target on Beyond Air (XAIR) to $2 from $6 and keeps a Buy rating on the shares following the fiscal Q3 report. The potential commercialization of Beyond Air’s second generation LungFit PH system “represents the key inflection point for driving sustainably high revenue growth and profitability,” the analyst tells investors in a research note. The firm reduced its sales estimates with the FDA’s approval decision not expected until the end of 2026.